OA10581A - Substituted n-(indole-2-carbonyl)-glycinamides andderivatives as antidiabetic agents - Google Patents

Substituted n-(indole-2-carbonyl)-glycinamides andderivatives as antidiabetic agents Download PDF

Info

Publication number
OA10581A
OA10581A OA60832A OA60832A OA10581A OA 10581 A OA10581 A OA 10581A OA 60832 A OA60832 A OA 60832A OA 60832 A OA60832 A OA 60832A OA 10581 A OA10581 A OA 10581A
Authority
OA
OAPI
Prior art keywords
alkyl
chloro
mono
compound
indole
Prior art date
Application number
OA60832A
Other languages
English (en)
Inventor
Bernard Hulin
Judith Lee Treadway
William Holt Martin
Dennis Jay Hoover
Douglas Phillips
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA10581A publication Critical patent/OA10581A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
OA60832A 1995-06-06 1996-05-31 Substituted n-(indole-2-carbonyl)-glycinamides andderivatives as antidiabetic agents OA10581A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000442 WO1996039384A1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
OA10581A true OA10581A (en) 2002-08-28

Family

ID=11004338

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60832A OA10581A (en) 1995-06-06 1996-05-31 Substituted n-(indole-2-carbonyl)-glycinamides andderivatives as antidiabetic agents

Country Status (37)

Country Link
US (1) US6107329A (bg)
EP (1) EP0832065B1 (bg)
JP (1) JP3314938B2 (bg)
KR (1) KR100191992B1 (bg)
CN (2) CN1142492A (bg)
AP (1) AP623A (bg)
AR (1) AR003955A1 (bg)
AT (1) ATE206702T1 (bg)
AU (1) AU701465B2 (bg)
BG (1) BG100547A (bg)
BR (1) BR9602542A (bg)
CA (2) CA2342471C (bg)
CO (1) CO4700440A1 (bg)
CZ (1) CZ157396A3 (bg)
DE (1) DE69523182T2 (bg)
DK (1) DK0832065T3 (bg)
FI (1) FI974436A (bg)
HR (1) HRP960244A2 (bg)
HU (1) HUP9601475A2 (bg)
IL (1) IL118029A0 (bg)
IS (1) IS4341A (bg)
LV (1) LV11613B (bg)
MA (1) MA23866A1 (bg)
MX (1) MX9709875A (bg)
NO (2) NO306398B1 (bg)
NZ (1) NZ286460A (bg)
OA (1) OA10581A (bg)
PL (1) PL314561A1 (bg)
RU (1) RU2143424C1 (bg)
SG (1) SG44947A1 (bg)
SI (1) SI9600177A (bg)
SK (1) SK69996A3 (bg)
TN (1) TNSN96072A1 (bg)
TR (1) TR199600456A2 (bg)
TW (1) TW346485B (bg)
WO (1) WO1996039384A1 (bg)
YU (1) YU34896A (bg)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9709875A (es) * 1995-06-06 1998-03-31 Pfizer N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas.
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
WO1998046243A2 (en) 1997-04-15 1998-10-22 Csir Pharmaceutical compositions having appetite suppressant activity
UA57811C2 (uk) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP0978279A1 (en) * 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
EP1147214B1 (en) 1999-01-13 2011-01-05 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6316489B1 (en) 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6410750B1 (en) * 1999-06-18 2002-06-25 Pfizer Inc. Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US20060160740A1 (en) * 1999-10-21 2006-07-20 Suad Efendic Use of GLP-1 or analogs in treatment of stroke
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
KR20020047321A (ko) 1999-11-04 2002-06-21 오르토-맥네일 파마슈티칼, 인코퍼레이티드 바소프레신 길항제로서의 비펩티드 치환 벤조티아제핀
ATE346613T1 (de) 2000-01-21 2006-12-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
PE20011184A1 (es) * 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
AU779266B2 (en) * 2000-05-11 2005-01-13 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
ATE470448T1 (de) 2000-10-20 2010-06-15 Amylin Pharmaceuticals Inc Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1392679B1 (de) * 2001-05-10 2005-11-02 Solvay Pharmaceuticals GmbH Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO2003035621A1 (en) 2001-10-22 2003-05-01 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
EP1452526A1 (en) * 2001-10-29 2004-09-01 Japan Tobacco Inc. Indole compound and medicinal use thereof
FR2834214B1 (fr) * 2001-12-28 2004-09-24 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
CN1592749A (zh) * 2002-01-18 2005-03-09 辉瑞产品公司 用于制备糖原磷酸化酶抑制剂的中间体
MXPA03000966A (es) * 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
AU2003227360A1 (en) * 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
CA2503727A1 (en) * 2002-11-07 2004-05-21 Pfizer Products Inc. Anti-diabetic agents
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
WO2004071458A2 (en) * 2003-02-13 2004-08-26 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
EP1615900A1 (en) * 2003-04-01 2006-01-18 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
MXPA05011176A (es) * 2003-04-17 2005-12-14 Pfizer Prod Inc Derivados de carboxamida como agentes antidiabeticos.
MXPA05011702A (es) * 2003-04-30 2006-01-23 Pfizer Prod Inc Agentes antidiabeticos.
WO2004103958A2 (en) * 2003-05-19 2004-12-02 Michigan State University Preparation of hymenialdisine derivatives and use thereof
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
JP2006528702A (ja) * 2003-05-21 2006-12-21 プロシディオン・リミテッド グリコーゲンホスホリラーゼのピロロピリジン−２−カルボン酸アミドインヒビター
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
WO2004112701A2 (en) * 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PT1689757E (pt) 2003-11-12 2014-12-09 Sino Med Internat Alliance Inc Compostos heterocíclicos de ácido borónico
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
JP2007527904A (ja) 2004-03-08 2007-10-04 プロシディオン・リミテッド グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
CA2573848A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
EP1819332B1 (en) 2004-12-02 2009-03-11 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amides
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
US8691835B2 (en) 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
BRPI0609464A2 (pt) * 2005-05-23 2010-04-13 Japan Tobacco Inc composto de pirazol e agente terapêutico para diabetes compreendendo o mesmo
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
MY159522A (en) 2005-09-14 2017-01-13 Takeda Pharmaceuticals Co Administration of dipeptidyl peptidase inhibitors
CN100519524C (zh) * 2005-09-29 2009-07-29 中国人民解放军军事医学科学院毒物药物研究所 吲哚丙烯酸衍生物及其用于制备免疫抑制剂的用途
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
CN101516834B (zh) * 2006-09-13 2013-04-03 塞诺菲-安万特股份有限公司 用作凝血因子IXa抑制剂的异丝氨酸衍生物
EP2096111A1 (en) * 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazoles and use thereof as drugs
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
WO2011028195A2 (en) * 2006-12-18 2011-03-10 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.
CN101279955B (zh) * 2007-04-03 2012-11-28 北京摩力克科技有限公司 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途
AR070398A1 (es) * 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
BRPI0911444B8 (pt) 2008-04-28 2021-05-25 Janssen Pharmaceutica Nv benzoimidazóis como inibidores de prolil hidroxilase e composição farmacêutica que os compreende
EA201100189A1 (ru) * 2008-07-15 2011-08-30 Новартис Аг Гетероарильные производные в качестве ингибиторов dgat1
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
CN102453001B (zh) * 2010-10-22 2016-06-01 中国医学科学院药物研究所 硫代吗啉类化合物及其制备方法和用途
US9409880B2 (en) * 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
CA2835220A1 (en) * 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
EP3091009B1 (en) 2011-10-25 2018-08-29 Janssen Pharmaceutica NV Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
WO2013133685A1 (en) 2012-03-09 2013-09-12 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
CN103497181B (zh) 2013-09-30 2016-03-30 承德医学院 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途
JP2017506666A (ja) * 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108329330B (zh) * 2017-01-20 2021-05-04 复旦大学 2-苄氧苯基噁唑并吡啶类化合物及其药物用途
CN108191845A (zh) * 2018-02-12 2018-06-22 李化绪 一种异恶唑亚氨基类化合物及其在降血脂药物中的应用
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764610A (en) * 1981-07-16 1988-08-16 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
US4836846A (en) * 1981-07-16 1989-06-06 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
NZ202232A (en) * 1981-11-06 1985-08-16 Smithkline Beckman Corp N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
US4933325A (en) * 1985-08-14 1990-06-12 G. D. Searle & Co. Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides
US4757151A (en) * 1985-11-14 1988-07-12 Warner-Lambert Company 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl]
US4902708A (en) * 1985-12-31 1990-02-20 Biomeasure, Inc. CCK antagonists
US5089638A (en) * 1986-06-16 1992-02-18 Merck & Co., Inc. Amino acid analogs as CCK-antagonists
MY103189A (en) * 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
WO1988003022A1 (en) * 1986-10-31 1988-05-05 Pfizer Inc. Relatively low molecular weight polypeptides as renin inhibitors
US5034376A (en) * 1986-10-31 1991-07-23 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US5095004A (en) * 1987-03-25 1992-03-10 Bio-Mega Inc. Fluorine containing atrial natriuretic peptides
EP0288965A2 (de) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptide mit Phospholipase A2- hemmender Wirkung
US5128346A (en) * 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
US5250517A (en) * 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
JPH03503650A (ja) * 1988-04-05 1991-08-15 アボツト・ラボラトリーズ Ｃｃｋアンタゴニストとしてのトリプトファン誘導体
US4904846A (en) * 1988-04-29 1990-02-27 Augustin Oscadal Oil filled body heater
GB8810203D0 (en) * 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
US5010089A (en) * 1988-08-12 1991-04-23 Biomeasure, Inc. CCK antagonists and their use in treating gastrointestinal disorders
FR2643371B1 (fr) * 1989-02-17 1993-11-05 Roussel Uclaf Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
IE902238A1 (en) * 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
EP0431520B1 (en) * 1989-12-04 1995-02-08 G.D. Searle & Co. Heterocyclic acyl aminodiol beta-amino acid derivatives
DE69101835T2 (de) * 1990-02-09 1994-08-18 Rhone Poulenc Rorer Sa N-phenyl-n-acetamidoglycinamide, ihre herstellung und medikamente, die sie enthalten.
JPH05504968A (ja) * 1990-03-07 1993-07-29 ローン―プーラン・ロレ・ソシエテ・アノニム グリシンアミド誘導体、その製造及びそれを含む医薬品
JPH03294253A (ja) * 1990-04-12 1991-12-25 Shionogi & Co Ltd 消化管ホルモン拮抗物質
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
GB9206757D0 (en) * 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1994006755A1 (en) * 1992-09-18 1994-03-31 Japan Tobacco Inc. Alcohol derivative having renin-inhibiting activity and use thereof
WO1994007815A2 (en) * 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
EP0764151A2 (en) * 1994-06-10 1997-03-26 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
MX9709875A (es) * 1995-06-06 1998-03-31 Pfizer N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas.

Also Published As

Publication number Publication date
CN1098838C (zh) 2003-01-15
TR199600456A2 (tr) 1996-12-21
NZ286460A (en) 1998-09-24
NO961664D0 (no) 1996-04-25
AU701465B2 (en) 1999-01-28
SK69996A3 (en) 1997-08-06
ATE206702T1 (de) 2001-10-15
DE69523182T2 (de) 2002-02-07
BR9602542A (pt) 1998-10-27
SG44947A1 (en) 1997-12-19
HUP9601475A2 (hu) 1998-09-28
NO990405L (no) 1999-01-28
LV11613B (en) 1997-04-20
JP3314938B2 (ja) 2002-08-19
US6107329A (en) 2000-08-22
NO306398B1 (no) 1999-11-01
CN1140709A (zh) 1997-01-22
EP0832065B1 (en) 2001-10-10
TNSN96072A1 (fr) 2005-03-15
CA2342471C (en) 2002-10-29
NO961664L (no) 1996-12-09
LV11613A (lv) 1996-12-20
TW346485B (en) 1998-12-01
BG100547A (bg) 1996-12-31
KR100191992B1 (ko) 1999-06-15
CN1142492A (zh) 1997-02-12
AP623A (en) 1997-12-19
CA2224062A1 (en) 1996-12-12
CO4700440A1 (es) 1998-12-29
AU5462696A (en) 1996-12-19
MX9709875A (es) 1998-03-31
DE69523182D1 (en) 2001-11-15
DK0832065T3 (da) 2001-11-19
CA2342471A1 (en) 1996-12-12
KR970001322A (ko) 1997-01-24
JPH10511687A (ja) 1998-11-10
CZ157396A3 (en) 1997-03-12
RU2143424C1 (ru) 1999-12-27
HRP960244A2 (en) 1997-12-31
FI974436A0 (fi) 1997-12-05
IS4341A (is) 1996-12-07
SI9600177A (en) 1997-02-28
YU34896A (sh) 1999-09-27
EP0832065A1 (en) 1998-04-01
MA23866A1 (fr) 1996-12-31
IL118029A0 (en) 1996-08-04
AP9600803A0 (en) 1996-04-30
CA2224062C (en) 2001-09-04
PL314561A1 (en) 1996-12-09
NO990405D0 (no) 1999-01-28
HU9601475D0 (en) 1996-07-29
FI974436A (fi) 1998-01-27
WO1996039384A1 (en) 1996-12-12
AR003955A1 (es) 1998-09-30

Similar Documents

Publication Publication Date Title
OA10581A (en) Substituted n-(indole-2-carbonyl)-glycinamides andderivatives as antidiabetic agents
CA2223625C (en) Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
US6277877B1 (en) Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
BG104435A (bg) Комбинация от инхибитор на алдозоредуктаза и инхибитор на гликоген фосфорилаза
EP1134213B1 (en) Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides
US6846820B2 (en) Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors
DE69534574T2 (de) Verfahren zur Herstellung von substituierten N-(Indol-2-carbonyl)-glycinamiden